ACADIA to Host Conference Call and Webcast on Monday, November 9,
2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Nov. 2, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the third quarter ended September 30, 2009 on Monday, November 9, 2009,
after the U.S. financial markets close. ACADIA's management will host a
conference call and webcast on Monday, November 9, 2009, at 5:00 p.m.
Eastern Time to discuss ACADIA’s financial results and development
programs.
The conference call may be accessed by dialing 866-510-0707 for
participants in the U.S. or Canada and 617-597-5376 for international
callers (reference passcode 92783090). A telephone replay of the
conference call may be accessed through November 23, 2009 by dialing
888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for
international callers (reference passcode 21130876). The conference call
also will be webcast live on ACADIA’s website, www.acadia-pharm.com,
under the investors section and will be archived there until November
23, 2009.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for
central nervous system disorders. ACADIA’s product candidates include
pimavanserin in Phase III for Parkinson’s disease psychosis in
collaboration with Biovail, a product candidate in Phase II for chronic
pain and a product candidate in Phase I for glaucoma, both in
collaboration with Allergan, and AM-831 in IND-track development in
collaboration with Meiji Seika Kaisha. All of the product candidates in
ACADIA’s pipeline emanate from discoveries made using its proprietary
drug discovery platform. ACADIA maintains a website at www.acadia-pharm.com
to which ACADIA regularly posts copies of its press releases as well as
additional information and through which interested parties can
subscribe to receive email alerts.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Vice
President and Chief Financial Officer
858-558-2871